Minova Pharma
Short-termed Medical Equipment rental.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor | €0.0 | round | |
* | CNY100m | Early VC | |
| Total Funding | 000k | ||
Related Content
Established in 2021, Minova Pharma is a pharmaceutical developer headquartered in Nanjing, China, focusing on the specialized fields of mental health and medical aesthetics. The company was founded by Fei Liu, who previously held a position at Jiangsu Simcere Pharmaceutical Co., Ltd. and later founded Nanjing Simnovtec pharmaceutical. Minova Pharma is dedicated to the research and development of treatments for disfiguring diseases and psychiatric disorders.
The company's core business revolves around developing small molecule drugs and complex formulations. Its product pipeline addresses a range of conditions including depression, hair loss, acne, photodamage, pigmentation, scarring, and localized fat accumulation. To support its R&D efforts, Minova Pharma has established several key technology platforms, including a system for phenotype-based drug screening, a small molecule total synthesis platform, and a novel drug delivery system platform. The business model is centered on advancing its proprietary drug candidates through clinical trials and eventually to market. As a private entity, it secures funding from investors to finance its research and development operations.
Minova Pharma has achieved significant financial milestones since its inception, raising over CNY 100 million in a Series A funding round by July 2022 and securing an additional CNY 100 million in a pre-Series B round in January 2024. Key investors include Oriza Holdings, Kaitai Capital, and Wenzhou Investment. The company anticipates moving its treatments for hair loss and photoaging into clinical development in 2024, signaling a crucial step towards commercialization.
Keywords: pharmaceutical developer, mental health drugs, medical beauty, dermatology, psychiatric disorders, small molecule drugs, drug discovery, clinical development, hair loss treatment, acne treatment, photodamage therapy, aesthetic medicine, phenotype screening, specialty pharmaceuticals, HealthTech, Nanjing, Fei Liu, Oriza Holdings, Kaitai Capital, disfiguring diseases